[根据ERK/p38 MAPK信号通路对性结肠炎大鼠Tripterygium糖化物的保护作用]
Hui-Rong Xiao1, Hui-Qun Ma2, Cheng-Cheng Wu3
1Jiangxi University of Chinese Medicine Nanchang 330004, China Affiliated Hospital of Jiangxi University of Chinese Medicine Nanchang 330006, China.
概括
三糖化物 (TG) 通过减少炎症和促进愈合,有效地治疗大肠炎在老鼠. 这种治疗效果与细胞外信号调节激酶/p38基因激活蛋白激酶 (ERK/p38 MAPK) 信号通路的调节有关.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,治疗选择有限.
- 细胞外信号调节激酶/p38基因激活蛋白激酶 (ERK/p38 MAPK) 途径与炎症反应有关.
- 三糖化物 (TG) 是一种具有潜在抗炎功能的中国传统药物.
研究的目的:
- 为了研究TG对实验性小鼠性结肠炎的治疗效果.
- 探索ERK/p38 MAPK信号通路在TG的作用机制中的作用.
主要方法:
- 在Wistar大鼠中诱导性结肠炎.
- 给出不同剂量的TG,一种阳性对照和一种途径抑制剂.
- 疾病活动指数 (DAI) 的评估,宏观和微观结肠损伤得分.
- 使用HE染色的组织病理学检查.
- 通过TUNEL测定检测亡.
- 使用ELISA测量血清炎症性细胞因子 (IL-1β,IL-6,TNF-α).
- 分析ERK/p38 MAPK通路蛋白和mRNA表达的分析,使用西方涂抹和PCR.
主要成果:
- 在剂量取决的方式,TG治疗显著降低了DAI,结肠损伤和亡.
- TG的使用降低了IL-1β,IL-6和TNF-α的血清水平.
- TG调节了酸化ERK和p38MAPK的表达,以及它们的mRNA水平.
- 途径抑制剂组表现出最显著的改善,这表明ERK/p38 MAPK途径的参与.
结论:
- 三糖化物 (TG) 在改善小鼠实验性性结肠炎方面表现出显著的有效性.
- TG治疗改善了结肠粘膜的完整性,减少了炎症,并增强了免疫功能.
- 在UC中TG的治疗机制可能涉及ERK/p38 MAPK信号通路的调制.
相关概念视频
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
347
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
347
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
356
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
356
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
542
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
542